ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

Lara H. El Touny,Curtis Hose,John Connelly,Erik Harris,Anne Monks,Angie B. Dull,Deborah F. Wilsker,Melinda G. Hollingshead,Michelle Gottholm-Ahalt,Sergio Y. Alcoser,Michael E. Mullendore,Ralph E. Parchment,James H. Doroshow,Beverly A. Teicher,Annamaria Rapisarda

DOI: https://doi.org/10.18632/oncotarget.28090

2021-10-12

Oncotarget

Abstract:The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMT^low/-ve/MMR^proficient patients benefit from TMZ treatment, indicating a need for additional patient selection criteria. We explored the role of ATR in mediating TMZ resistance and whether ATR inhibitors (ATRi) could reverse this resistance in multiple cancer lines. We observed that only 31% of MGMT^low/-ve/MMR^proficient patient-derived and established cancer lines are sensitive to TMZ at clinically relevant concentrations. TMZ treatment resulted in DNA damage signaling in both sensitive and resistant lines, but prolonged G₂/M arrest and cell death were exclusive to sensitive models. Inhibition of ATR but not ATM, sensitized the majority of resistant models to TMZ and resulted in measurable DNA damage and persistent growth inhibition. Also, compromised homologous recombination (HR) via RAD51 or BRCA1 loss only conferred sensitivity to TMZ when combined with an ATRi. Furthermore, low REV3L mRNA expression correlated with sensitivity to the TMZ and ATRi combination <i>in vitro</i> and <i>in vivo</i>. This suggests that HR defects and low REV3L levels could be useful selection criteria for enhanced clinical efficacy of an ATRi plus TMZ combination.